| Biologic Therapy |
1 |
1 |
| Tyrosine Kinase Inhibitor |
0 |
0.76 |
| Mantle Cell Lymphoma |
0 |
0.55 |
| Tyrosine Kinase |
0 |
0.54 |
| CAR-T |
0 |
0.46 |
| Lymphoma |
0 |
0.42 |
| Hodgkin Lymphoma |
0 |
0.39 |
| Toxicology |
0 |
0.34 |
| Antineoplastic Drug |
0 |
0.26 |
| Stem Cell Research and Therapy |
0 |
0.22 |
| Leukemia |
0 |
0.2 |
| Monoclonal Antibody |
0 |
0.18 |
| Autologous stem cell transplant |
0 |
0.13 |
| Cancer |
0 |
0.12 |
| Prognosis |
0 |
0.12 |
| Transplantation |
0 |
0.12 |
| Chronic Lymphocytic Leukemia |
0 |
0.09 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Antibody Drug Conjugates |
0 |
0.06 |
| Antigens |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Chemotherapy |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Texas |
0 |
0.06 |